PRESS RELEASES

Clerio Vision Hires Eye Care Industry Veteran to Lead Cornea Commercialization Efforts

John Weberg joins opthalmic technology firm to fuel growth 

OCTOBER 7, 2019 – ROCHESTER, N.Y. Clerio Vision has named John Weberg as Cornea Chief Commercialization Officer to further expand the development of its cornea business, which includes continued research and development, clinical trials and commercialization efforts. 

The company expects to use its Laser Induced Refractive Index Correction (LIRIC) technology to offer superior Fresnel lens diffractive optics patterns to correct presbyopia, myopia, hyperopia, astigmatism and higher order aberrations.   

“The technology that Clerio Vision is bringing forth will be so disruptive to ophthalmology, that it will revolutionize how we do business and change people’s lives for the better by offering a safe, noninvasive solution for most if not all the refractive diseases,” Weberg said. “I believe this technology will be seen as a significant life changing therapy for patients with a giant leap forward in safety and efficacy. ” 

Weberg, who most recently was global director of medical affairs for Johnson & Johnson’s surgical business, brings an in-depth knowledge of healthcare operations at all levels, from startup ventures to Fortune 100 companies. He is also known for his efforts at Visx, a refractive surgery provider, a company which was purchased by Advanced Medical Optics in a $1.27 billion deal in 2004. 

“We are extremely pleased to have John on board,” said Alex Zapesochny, CEO of Clerio. “His leadership and expertise in this industry, in building and growing Visx’s markets, will greatly enhance our strategies and execution as we propel Clerio forward.”

About Clerio Vision, Inc.

Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester.  The company’s contact lens and refractive surgery products are currently in clinical development.  The company has raised approximately  $40 million  in financing from Safar Partners, Stonehenge Growth Equity, Armory Square Ventures, prominent angel investors and the National Science Foundation.  The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories.

Clerio Vision Acquires Manufacturer of Extreme H2O Contact Lenses

Combination positions company to introduce next advance in multifocal contact lenses

JULY 15, 2019 – ROCHESTER, N.Y. – Clerio Vision, Inc., a developer of laser-based vision correction solutions, announced today that it has acquired Hydrogel Vision Corporation (HVC).  The transaction brings together HVC’s long-standing expertise in the manufacturing and distribution of high performance contact lenses with Clerio’s innovative product pipeline. 

HVC, founded in 2002, is best known for its Extreme H2O product line and its multiple differentiated offerings that personalize the contact lens wearing experience.  For instance, HVC offers lenses in multiple diameters, with smaller lenses to more comfortably fit those with smaller corneas or narrower eyelids, and larger lenses for those with larger corneas or for improved sports performance.  

HVC contacts are also made from a proprietary ultra-hydrating material that retains up to 99% of its moisture, which can help to minimize the dryness and itchiness that is often experienced by contact lens wearers late in the day, and may be especially helpful to those who work a lot with screens or live in dryer climates.  HVC also distributes the only disposable opaque color contacts for those with astigmatism. 

Clerio was founded in 2014 to commercialize breakthrough femtosecond laser research at the University of Rochester.  The company’s technology enables the laser writing of unique patterns into contact lenses that optimize visual acuity, including superior correction at both far and near distances for those with presbyopia.  Clerio’s multifocal contact lens product is currently in clinical development and is expected to be on the market in the next 18 months.  

“As Clerio began preparations for its first contact lens offering, we quickly identified HVC as a best-in-class manufacturing partner,” said Alex Zapesochny, Co-CEO of Clerio Vision.  “We are thrilled to have now fully joined forces with HVC and to further build on its history of offering innovative products of the highest quality.” 

HVC products are sold in 25 countries, either under the Extreme H2O brand or under one of several private label arrangements.  All HVC employees will be retained and its manufacturing and fulfillment activities will continue to be carried out in its locations in Sarasota, Florida.  

Financial details of the transaction were not disclosed.

About Clerio Vision, Inc.:

Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester.  The company’s contact lens and refractive surgery products are currently in clinical development.  The company has raised approximately $30 million in financing from Safar Partners, Stonehenge Growth Equity, Armory Square Ventures, prominent angel investors and the National Science Foundation.  The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories.

For more information about Extreme H2O lenses, visit: www.extremeh2ocontactlenses.com

For more information about Clerio, visit:www.cleriovision.com.  

Media Contact:

Trevor McCaw 

Clerio Vision, Inc.  

Phone: 1.650.440.6271

Email: tmccaw@cleriovision.com